Good Laboratory Practice (GLP) compliance obtained by IHU Strasbourg

Good Laboratory Practice (GLP) compliance obtained by IHU Strasbourg

The University Hospital Institute (IHU) of Strasbourg has become the first French facility to obtain recognition of compliance with good laboratory practice for the preclinical evaluation of medical devices.

Operating room of the experimental platform at the IHU Strasbourg

Operating room of the experimental platform at the IHU Strasbourg © IHU Strasbourg

Recognition by the ANSM

On October 21, following over two years of work, the French National Agency for the Safety of Medicines and Health Products (ANSM) awarded the Image-Guided Surgery Institute of Strasbourg recognition of compliance with Good Laboratory Practices. This recognition concerns implantable medical devices (vascular or digestive stents, surgical clips, prostheses) and diagnostic or treatment assistance devices, both hardware and software, including systems based on Artificial Intelligence.

The IHU in Strasbourg is the first academic institute in France, and one of the very first in Europe to obtain this recognition.

A guarantee for Industry

Certification of GLP compliance sets the IHU of Strasbourg apart from its peers for industry partners and collaborators. It allows them to simplify and accelerate their own accreditation processes, but also to test products before they are approved. Valid on the European market (CE marking), but also in all OECD member countries including the USA (FDA) and Japan, the accreditation represents the Industry’s confidence in trusting the IHU’s preclinical expertise.

An experimental platform and network of experts that are unique in the world

Une plateforme expérimentale et un réseau d’experts unique au monde

The IHU’s experimental platform is fitted with cutting-edge equipment in the fields of surgery, imaging, and minimally invasive therapies (flexible endoscopy, endovascular or percutaneous treatments, robot-assisted surgery). Since its creation, over fifty industry or academic laboratory professionals have been able to work in this platform in a wide range of fields, from hepato-gastroenterology, to cardiovascular studies, neurology and neurosurgery, as well as urology, interventional pneumology, thoracic surgery, gynaecology, and orthopaedics. By coming to the IHU in Strasbourg, manufacturers benefit from the expertise and tailor-made services of an internationally recognized research institute to test and verify the safety and expected effectiveness of their medical devices.

According to IHU Director, Benoît Gallix, “The recognition of GLP compliance should enable us to double this contracted research for industry professionals within two years”.

Customized services to meet the needs of the market

We provide tailor-made services to meet the needs of our customers. We accompany them from the preparation of their research plan by advising them on the experiments most suited to meeting their objectives and go as far as providing them with a complete report that can include a file for submissions to regulatory authorities.

Our experts are personally involved in these studies so as to contribute their knowledge and expertise and may also participate in the improvement of the product or the procedure thanks to their experience feedback.

The services we offer also apply to the organization of training sessions with industrial customers to train practitioners in the use of a new medical device or a new therapeutic approach. More particularly, we have a catalogue of preclinical in vivo and ex vivo models that we can adapt to the needs of our customers (catalogue provided on request) for a tailor-made course, adapted to the specificities of the device.

Télécharger la brochure de la plateforme expérimentale (en anglais)Download the brochure of the experimental platform

Read the press release – 08/11/2021 by Noiizy

CLINICCAI & AWARD IHU

CLINICCAI & AWARD IHU

IHU Strasbourg and ICube have successfully organized CLINICCAI, the first clinical day at the international MICCAI conference on Medical Image Computing and Computer Assisted Interventions on September 29. CLINICCAI and MICCAI, initially planned to be hosted in Strasbourg, took place virtually this year. CLINICCAI featured 23 oral presentations by clinicians, who showed and discussed their research on the more translational and clinical aspects of medical image computing, computer-assisted interventions, and medical robotics. The event was a great success!

screenshot_team_CLINICCAI

An interview of Prof. Nicolas Padoy about CLINICCAI (p. 22):
https://www.rsipvision.com/MICCAI2021-Wednesday/

IHU Strasbourg has sponsored the best presentation awards, attributed to:

Fiona Kolbinger, for the work:
Artificial Intelligence for context-aware surgical guidance during robot-assisted rectal resection – an exploratory feasibility study
Kolbinger, Fiona; Stefan Leger; Matthias Carstens; Franziska M. Rinner; Stefanie Krell; Alexander Chernykh; Sebastian Bodenstedt; Johannes Fritzmann; Marius Distler; Jürgen Weitz; Stefanie Speidel

Cesare Hassan, for the work:
Optical diagnosis assisted by real-time Artificial Intelligence for <5 mm rectosigmoid polyps (Artificial intelligence BLI Characterization; ABC study) Rondonotti Emanuele, Hassan Cesare, Tamanini Giacomo, Antonelli Giulio et al.

These awards include a 2-days research visit at IHU Strasbourg, free of charge -congratulations to the awardees!

cliniccai

Predictive and personalized medicine of pancreatic cancer I AAP générique ANR 2021 I PRCI Projects

Predictive and personalized medicine of pancreatic cancer I AAP générique ANR 2021 I PRCI Projects

Project CancerProfile
IHU Strasbourg + Luxembourg Institute of Health.

With a 5-year survival rate remaining in the single digits, pancreatic ductal adenocarcinoma cancer (PDAC) has the poorest prognosis of all digestive cancers due to the lack of early diagnosis and limited response to treatments. It is the deadliest worldwide, with a mortality which is predicted to increase in western countries as population age and levels of obesity rise. It often develops without apparent symptoms, and the diagnosis is typically established late in the progression of the disease, at which point only 15 to 20% of patients are eligible for surgical resection, which remains the only curative treatment. Thus, palliative chemotherapy remains a mainstay in the management of this disease. However, the strong resistance to currently used chemotherapeutic agents represents a major treatment bottleneck, and the development of effective therapeutic approaches to fight PDAC is still an urgent medical need.

CANCER PROFILE

CancerProfile is a multidisciplinary translational research project aimed at improveing early diagnosis and prediction of PDAC tumor response to treatments, combining cutting edge Artificial Intelligence-augmented histological imaging and innovative functional profiling of patient tumor-derived organoids, to foster precision medicine of PDAC. The project will lay the foundation for a large clinical study to evaluate the implementation of personalized treatment for PDAC patients. It will lead to the establishment of a unique biobanking and database organization, that can serve as a platform for other basic and translational European research projects.

Artificial Intelligence for Safer Surgery

Artificial Intelligence for Safer Surgery

Clinicians and computer scientists at CAMMA, a joint research group between IHU Strasbourg and ICube/University of Strasbourg, have teamed up to improve safety in laparoscopic cholecystectomy using artificial intelligence (AI).

The Strasbourg-based team first proposed the 5-second rule, a simple yet effective cognitive aid to promote the implementation of guidelines for safe cholecystectomy. In an article published in the Journal of the American College of Surgeons, they demonstrate that a 5-second-long intraoperative time out to recall best practices induces a three-fold increase in the achievement of the Critical View of Safety, an essential step to prevent bile duct injuries.

JACS

In a commentary entitled “Time to Stop and Pause”, the lead author of the worldwide guidelines on safe cholecystectomy Dr L Michael Brunt writes:

“Of all the quality improvement measures implemented in surgery and medicine over the last many years, the simple act of a momentary pause to stop, look, and reflect before proceeding with an irreversible step in an operation, may arguably have one of the highest benefit-to-risk ratios, especially given the minimal time to do it and the considerable potential upside for enhancing patient safety” 

Concurrently, the same team has developed and published on the Annals of Surgery DeepCVS, the first AI model capable of recognizing important anatomical structures and automatically assessing the achievement of the aforementioned safety view to provide surgeons with intraoperative decision support.

To try DeepCVS, please visit: https://deepcvs.ihu-strasbourg.eu

Finally, in a second article in the Annals of Surgery, the team presents EndoDigest, a computer vision platform providing short videos selectively documenting critical steps of procedures to promote transparency, research, and education in surgery.

The multidisciplinary team led by Prof. Nicolas Padoy is now starting collaborations with other surgical centers and industrial partners like NVIDIA to validate and optimize these prototypes, essential steps to translate these and other AI algorithms to operating rooms and finally generate value for patients, surgeons, and healthcare systems.

CAMMA_NVIDIA_OR_BD

To learn more or contact the team, please visit:
http://camma.u-strasbg.fr

COVID-19 Related olfactory disorders: 96% Recovery at 1 year

COVID-19 Related olfactory disorders: 96% Recovery at 1 year

In an article published in the medical journal JAMA Network Open, the ENT team of the University Hospitals of Strasbourg (Dr. Marion Renaud), with the support of the IHU Strasbourg, is the first to describe the one-year prognosis of post-COVID-19–related anosmia. Their results are reassuring!  A large majority (85%) of patients regained a fairly normal sense of smell within the first 6 months and 96% of patients had completely recovered their sense of smell within a year!

Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis

Crédit photo : https://jamanetwork.com/

 

Read the full article at JAMA Network Open

The article was read more than 10,000 times in 72 hours and received great news coverage both nationally and internationally, with more than 100 press articles, including:

HUS Strasbourg